Another finding of this study is that besides weight loss, IQP-AE-103 showed beneficial effects on lipid metabolism. A significantly higher proportion of subjects in the high-dose IQP-AE-103 group experienced a reduction in triglyceride levels at the end of the study compared with placebo. In subjects with higher baseline total cholesterol levels (>6.2 mmol/L), high dose of IQP-AE-103 was shown to significantly reduce total cholesterol and LDL-cholesterol (pre-post change). Therefore, current outcome suggests that long-term treatment with IQP-AE-103 could be beneficial for subjects with elevated blood lipid levels in reducing the risk of cardiovascular disease. This research confirms Redusure's role in appetite reduction by promoting pleasant feelings of fullness when taken before meals,' stated Holly Tully, VP of Marketing, InQpharm NA. 'The study also reveals just how effective these appetite-reducing properties are in helping individuals lose weight at a consistent, healthy rate.'

Hunger Buddy does not contain any ingredient of animal origin and has no added artificial, flavourings, salt or preservatives. Weight management treatments range from natural, oral solutions to risky, invasive surgical procedures. In the dietary supplement industry, new products constantly offer promises to dieters; yet, most are born from similar technology and mechanisms of action. Institute of Medicine, Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids (Macronutrients), The National Acadamy Press, Washington, DC, USA, 2005. B. Grube, et al., “IQP-VV-102, A Novel Proprietary Composition for Weight Reduction: A Double-Blind Randomized Clinical Trial for Evaluation of Efficacy and Safety,” Evidence-Based Complementary and Alternative Medicine: http://dx.doi.org/10.1155/2015/413075 (2015). The study evaluated the effectiveness and tolerability of Redusure (IQP-AK-102), a patent-pending fibre complex and key ingredient in bmiSMART's I-CONTROL appetite reducer, for promoting weight loss in overweight and obese individuals. Results found that subjects who received Redusure saw significantly higher weight reduction than those who received the placebo.For beneficial action of fibres on gastrointestinal transit, it is recommended to drink at least 2L of water a day. Slight constipation could occur in case of limited liquid intake. If constipation persists despite adequate fluid intake, please consult your healthcare professional. All XLS-Medical products carry the CE logo, indicating they have been assessed to meet high safety, health, and environmental protection requirements As an intellectual property attorney, I understand how important it is to have high quality legal representation for protecting valuable brand names.

Do not take Hunger Buddy during pregnancy or whilst breastfeeding, or if your BMI (Body Mass Index) is below 18.5. It is recommended that you calculate your BMI before and during use. Subjects underwent a 2-week run-in phase to assess the compliance to the study requirements and the recommended dietary regimen, before randomization for the 12-week treatment phase. Subjects were randomly allocated to either IQP-AE-103 high dose, IQP-AE-103 low dose, or the placebo group according to the randomization code provided by an independent statistician. Subjects were instructed to take two capsules of the investigational product three times daily, 15 minutes after each main meal (breakfast, lunch, and dinner), with a glass of water (250 ml). Each capsule of IQP-AE-103 high dose contained 330 mg dehydrated okra powder and 85 mg inulin, whereas low-dose capsules contained half the amount of okra powder and inulin; and placebo capsules contained standard excipients. All the capsules were identical in size and appearance. Dehydrated okra powder was obtained from whole okra pods ( Abelmoschus esculentus) that were cleaned, sliced, oven-dried at 60°C, and milled to form a fine powder. Inulin was extracted from freshly sliced chicory roots using hot water, followed by filtration and purification by discoloration and decalcification. The materials were tested for microbiological activity and contaminants, and inulin was tested for purity. The daily dosage of IQP-AE-103 was determined based on data obtained from a previous animal study that has shown efficacy in preventing weight gain and in increasing fecal excretion (data not shown). Considering the mode of action of the product, that is, reducing dietary fat absorption, the daily dosage was divided into 3 equal doses to be consumed after 3 main meals. Figure 3: Tanitol 14-week placebo-controlled, randomised, double-blind clinical trial results Weight loss through increased satiety Objective. This study was performed to determine the efficacy and tolerability/safety of IQP-AE-103 on body weight reduction in overweight to moderately obese adults. Methods. A double-blind, randomized, placebo-controlled trial involved one hundred and eight subjects (BMI between 25 and 35 kg/m 2) that were randomly assigned to either the low-dose or the high-dose IQP-AE-103 group, or the placebo group. Following a 2-week run-in period, subjects received two capsules of investigational product after three daily main meals for 12 weeks. Subjects were instructed to maintain a nutritionally balanced hypocaloric diet according to the individual’s energy requirement. Body weight, body fat, and waist and hip circumference were measured at baseline, and after 2, 4, 8, and 12 weeks. Subjects also rated their feelings of hunger and fullness using visual analogue scales, and food craving on a 5-point scale at the same time intervals. Blood samplings for safety laboratory parameters were taken before and at the end of the study. Results. After 12 weeks of intake, the high-dose IQP-AE-103 group had a significantly greater weight loss compared with the placebo (5.03 ± 2.50 kg vs. 0.98 ± 2.06 kg, respectively; ) and the low-dose group (3.01 ± 2.19 kg; ). The high-dose group experienced a decrease in body fat of 3.15 ± 2.41 kg compared with a decrease of 0.23 ± 2.74 kg for the placebo group ( ). High-dose IQP-AE-103 also decreased the feeling of hunger in 66% subjects. A beneficial effect of IQP-AE-103 on the lipid metabolism was also demonstrated in the subgroup of subjects with baseline total cholesterol levels above 6.2 mmol/L. No side effects related to the intake of IQP-AE-103 were reported. Conclusions. These findings indicate that IQP-AE-103 could be an effective and safe weight loss intervention. This trial is registered with NCT03058367. 1. Introduction There are three ways to upload your file: drag & drop, browse your hard drive or upload a PDF file from the cloud.B. Grube, et al., “A Natural Fiber Complex Reduces Body Weight in the Overweight and Obese: A Double-Blind, Randomized, Placebo-Controlled Study,” Obesity 21, 58–64 (2013). Please note that not all products available online are available in the stores. The RRP against which any savings comparisons we make to the listed sale For you, we are running many services free of cost. Those services are expensive to run, requiring multiple servers to process and encode the files.